Avedro, Inc. Announces Appointment of Patrick B. Jacques as Vice President of Sales
13 Marzo 2019 - 9:05PM
Avedro, Inc. (Nasdaq: AVDR) (“Avedro”), a leading commercial-stage
ophthalmic medical technology company focused on treating corneal
ectatic disorders and improving vision to reduce dependency on
eyeglasses or contact lenses, today announced the appointment of
Patrick B. Jacques as Vice President of Sales, effective
immediately. Reporting to James Schuermann, Avedro’s Chief Business
Officer, Mr. Jacques will be responsible for directing Avedro’s
U.S. sales strategy, building relationships with clinicians and
other key partners, and contributing to Avedro’s marketing
programs.
Mr. Jacques brings more than 20 years of sales and leadership
experience across various segments in ophthalmology and optometry
to Avedro. Mr. Jacques began his career with SPS Medical Supply and
held roles of increasing responsibility with Briot/Buchman and
Advanced Medical Optics. At Abbott Medical Optics, he managed
the sales organization for their refractive laser business in the
Western United States. Most recently at AcuFocus, which
transacted the KAMRA inlay business to CorneaGen in 2018, he was
responsible for the domestic launch of the corneal inlay product
for presbyopia and for building the company’s field commercial
organization.
“We are pleased to welcome Patrick to Avedro to lead our sales
efforts in the United States,” said Reza Zadno, PhD, President and
Chief Executive Officer of Avedro. “Patrick is a seasoned sales
leader with a track record of successfully driving adoption of new
ophthalmic technologies. We are confident that our Avedro Corneal
Remodeling Platform coupled with our talented and experienced team
will grow our leadership position in the treatment of progressive
keratoconus and expand treatment capabilities to address additional
conditions, such as refractive disorders.”
“I am very excited to be joining Avedro at such a pivotal time
in the company’s history. Avedro has made significant
progress with reimbursement, earning a unique J code from CMS and
securing positive coverage from America’s largest national
commercial payers, facilitating access to approximately 95 percent
of our estimated total U.S. addressable market. I am looking
forward to working with my network of refractive ophthalmic
customers to accelerate adoption of FDA approved cross-linking in
the United States and help more patients with this
sight-threatening disease,” said Mr. Jacques.
About Avedro, Inc.Avedro is a leading
commercial-stage ophthalmic medical technology company focused on
treating corneal ectatic disorders and improving vision to reduce
dependency on eyeglasses or contact lenses. Avedro’s proprietary
Corneal Remodeling Platform is designed to strengthen, stabilize
and reshape the cornea utilizing corneal cross-linking in minimally
invasive and non-invasive outpatient procedures to treat corneal
ectatic disorders and correct refractive conditions. The Avedro
Corneal Remodeling Platform is comprised of Avedro’s KXL and Mosaic
systems, each of which delivers ultraviolet A light, and a suite of
proprietary single-use riboflavin drug formulations, which, when
applied together to the cornea, induce a biochemical reaction
called corneal collagen cross-linking.
Forward-Looking Statements
This press release contains “forward-looking
statements” within the meaning of the Private Securities Litigation
Reform Act of 1995, including, but are not limited to, statements
about the market opportunity for the Avedro Corneal Remodeling
Platform and the rate of adoption of FDA approved cross-linking
procedures. Words such as “anticipates,” “believes,” “expects,”
“intends,” “projects,” “anticipates,” and “future” or similar
expressions are intended to identify forward-looking statements.
Any forward-looking statements are based on management’s current
expectations of future events and are subject to a number of risks
and uncertainties that could cause actual results to differ
materially and adversely from those set forth in or implied by such
forward-looking statements. For a discussion of risks and
uncertainties and other important factors, any of which could cause
Avedro’s actual results to differ from those contained in the
forward-looking statements, see the section titled “Risk Factors”
in Avedro’s prospectus dated February 13, 2019 filed pursuant to
Rule 424(b)(4) as well as discussions of potential risks,
uncertainties and other important factors in Avedro’s subsequent
filings with the Securities and Exchange Commission. All
information in this press release is as of the date of the release,
and Avedro undertakes no duty to update this information unless
required by law.
Avedro ContactDavid Iannetta Avedro, Inc.Phone:
1-844-528-3376 info@avedro.com
Media ContactMichele Gray Gray Communications,
LLC. Phone: 917-449-9250 michele_gray@me.com
Investor ContactGreg Chodaczek or Lynn
LewisPhone: 646-924-1769investors@avedro.com
Grafico Azioni Avedro (NASDAQ:AVDR)
Storico
Da Mag 2024 a Giu 2024
Grafico Azioni Avedro (NASDAQ:AVDR)
Storico
Da Giu 2023 a Giu 2024